🔎 Trials Near Me

Gara Jalqabaatti › Kansara Qara'a Non-Small Cell › Ohio › Parma

Qorannoo klinikaalii Kansara Qara'a Non-Small Cell Parma, OH keessatti

Qorannoo 4 Kansara Qara'a Non-Small Cell f Parma fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Namoota walitti qabaa jiraSadarkaa 3
  • Cleveland Clinic Cancer Center Independence, Independence · Miili 5 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04267848

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Namoota walitti qabaa jiraSadarkaa 3
  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon · Miili 17 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07144280

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Namoota walitti qabaa jiraSadarkaa 3
  • University Hospitals Seidman Cancer Center at UH Avon Health Center, Avon · Miili 17 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT06758401

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Namoota walitti qabaa jiraSadarkaa 3
  • Local Institution - 0519, Elyria · Miili 20 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06561386

Qorannoo Kansara Qara'a Non-Small Cell magaalota biroo keessatti

Qorannoo biroo Parma keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.